US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Medicus Pharma Ltd.

0.2574

-0.0144-5.30%

Post-market: 0.26920.0118+4.58%19:38 EDT

Volume:826.14K

Turnover:215.07K

Market Cap:16.26M

PE:-0.16

High:0.2750

Open:0.2700

Low:0.2550

Close:0.2718

52wk High:3.05

52wk Low:0.2425

Shares:63.18M

Float Shares:56.90M

Volume Ratio:0.40

T/O Rate:1.45%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6597

EPS(LYR):-2.7356

ROE:-7446.11%

ROA:-110.67%

PB:-9.22

PE(LYR):-0.09

Loading ...

Overview Company News Filings

Medicus Pharma Ltd reports results for the quarter ended December 31 - Earnings Summary

Medicus Pharma FY2025 announces SkinJect SKNJCT-003 topline results; net loss climbs to $35.4 million

Medicus Pharma Q4 EPS $(0.83) Misses $(0.15) Estimate

Benzinga Earnings

Medicus Pharma FY2025 net loss more than doubled to $35.4 million; operating loss tripled to $34.4 million

Medicus Pharma Ltd expected to post a loss of 15 cents a share - Earnings Preview

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Showcases Strong Phase 2 SkinJect Data Ahead of Fireside Chat

Medicus Pharma executives to join Brookline Capital Markets fireside chat on SkinJect Phase 2 results showing 73% clearance

BRIEF-Medicus Pharma Announces Skinject® Phase 2 Principal Investigator And Key Opinion Leader (Kol), Babar K. Rao MD, Faad, To Provide Clinical Interpretation Of Positive Data During Business Update Webcast On March 26

Medicus Pharma reports 73% clinical clearance in SkinJect Phase 2 nodular basal cell carcinoma trial

Medicus Pharma to Spotlight AI-Driven Drug Development at Longwood Miami CEO Forum

Medicus Pharma CEO to speak at Longwood Miami CEO Forum panel

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Highlights Strong Phase 2 SkinJect Results in Basal Cell Carcinoma

Medicus Pharma provides interpretation of Phase 2 SkinJect dataset

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Medicus Pharma Raises Equity Financing, Reduces Yorkville Debenture

Medicus Pharma Sells 4.47M Shares to Yorkville for $3.85M Under SEPA

Medicus Pharma Reports Phase 2 SkinJect D-MNA Data Showing 73% Clinical Clearance in Basal Cell Carcinoma

Medicus Pharma Reports Positive Phase 2 Sknjct-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (Cr) at Day 57 in 200ΜG Cohort

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/MDCX/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":0.2574,"timestamp":1787601600000,"preClose":0.2718,"halted":0,"volume":826139,"hourTrading":{"tag":"盘后","latestPrice":0.2692,"preClose":0.2574,"latestTime":"19:38 EDT","volume":4089,"amount":1058.95400892,"timestamp":1787614682958,"change":0.0118,"changeRate":0.045843,"amplitude":0.052059},"delay":0,"changeRate":-0.052980132450331015,"floatShares":56901000,"shares":63180610,"eps":-1.659689,"marketStatus":"Post-Mkt","change":-0.0144,"latestTime":"08-24 19:50:35 EDT","open":0.27,"high":0.275,"low":0.255,"amount":215071.88867542002,"amplitude":0.073584,"askPrice":0.275,"askSize":5000,"bidPrice":0.2564,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.659689,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":0.2718,"preHourTrading":{"tag":"盘前","latestPrice":0.27,"preClose":0.2718,"latestTime":"09:21 EDT","volume":7422,"amount":2017.2405951,"timestamp":1787577687274,"change":-0.0018,"changeRate":-0.006623,"amplitude":0.036792},"postHourTrading":{"tag":"盘后","latestPrice":0.2692,"preClose":0.2574,"latestTime":"19:38 EDT","volume":4089,"amount":1058.95400892,"timestamp":1787614682958,"change":0.0118,"changeRate":0.045843,"amplitude":0.052059},"volumeRatio":0.404229},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":56901000,"roa":"-110.67%","roe":"-7446.11%","lyrEps":-2.735593,"volumeRatio":0.404229,"shares":63180610,"dividePrice":0,"high":0.275,"amplitude":0.073584,"preClose":0.2718,"low":0.255,"week52Low":0.2425,"pbRate":"-9.22","week52High":3.05,"institutionHeld":0,"latestPrice":0.2574,"committee":-0.960784,"eps":-1.659689,"divideRate":0,"volume":826139,"delay":0,"ttmEps":-1.659689,"open":0.27,"prevYearClose":1.53,"prevWeekClose":0.2718,"prevMonthClose":0.2752,"prevQuarterClose":0.4463,"fiveDayClose":0.26,"twentyDayClose":0.3182,"sixtyDayClose":0.3293},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"MDCX","fiscalQuarterEnding":"2026/06","expectedEps":-0.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2026-05-14","symbol":"MDCX","fiscalQuarterEnding":"2026/03","expectedEps":-0.18,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.31},{"market":"US","date":"2026-03-25","symbol":"MDCX","fiscalQuarterEnding":"2025/12","expectedEps":-0.32,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774411200000,"reportTimeType":"post","actualEps":-0.82},{"date":"2025-11-14","symbol":"MDCX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763154000000,"name":null,"time":"Post-Mkt","dateTimestamp":1763096400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1785297600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MDCX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MDCX","date":"2026-08-21","current":-0.155511,"percent":0.899194,"low":-3.23298,"twenty":-2.211687,"median":-0.793282,"eighty":-0.354379,"high":-0.235266,"avg":-1.122787,"sd":0.953831,"marketCap":17197762},"quantilePoints":[{"date":"2025-08-29","current":-2.084531,"twenty":-2.272139,"median":-2.126221,"eighty":-2.109545,"marketCap":35632532},{"date":"2025-09-05","current":-1.907346,"twenty":-2.205434,"median":-2.115799,"eighty":-2.053263,"marketCap":32603766},{"date":"2025-09-12","current":-2.345097,"twenty":-2.211687,"median":-2.12101,"eighty":-2.053263,"marketCap":40086598},{"date":"2025-09-19","current":-2.532705,"twenty":-2.511859,"median":-2.178335,"eighty":-2.080362,"marketCap":43293526},{"date":"2025-09-26","current":-2.817408,"twenty":-2.759151,"median":-2.287772,"eighty":-2.103292,"marketCap":48160186},{"date":"2025-10-03","current":-3.005474,"twenty":-2.869667,"median":-2.511859,"eighty":-2.115799,"marketCap":51374941},{"date":"2025-10-10","current":-3.005474,"twenty":-2.994879,"median":-2.558762,"eighty":-2.122052,"marketCap":51374941},{"date":"2025-10-17","current":-2.885734,"twenty":-2.976858,"median":-2.720313,"eighty":-2.151236,"marketCap":49328130},{"date":"2025-10-24","current":-2.909682,"twenty":-2.974342,"median":-2.774974,"eighty":-2.174166,"marketCap":49737492},{"date":"2025-10-31","current":-2.957578,"twenty":-2.974342,"median":-2.817408,"eighty":-2.178335,"marketCap":50556216},{"date":"2025-11-07","current":-2.897708,"twenty":-2.962368,"median":-2.809662,"eighty":-2.228364,"marketCap":49532811},{"date":"2025-11-14","current":-2.706124,"twenty":-2.950394,"median":-2.817408,"eighty":-2.292984,"marketCap":46257915},{"date":"2025-11-21","current":-1.28141,"twenty":-2.950394,"median":-2.789942,"eighty":-2.178335,"marketCap":44939453},{"date":"2025-11-28","current":-1.355609,"twenty":-2.936025,"median":-2.763,"eighty":-2.119968,"marketCap":48464116},{"date":"2025-12-05","current":-1.183077,"twenty":-2.916866,"median":-2.742046,"eighty":-2.04284,"marketCap":42295956},{"date":"2025-12-12","current":-1.201563,"twenty":-2.904892,"median":-2.700137,"eighty":-1.376181,"marketCap":42956830},{"date":"2025-12-19","current":-1.022869,"twenty":-2.897708,"median":-2.63428,"eighty":-1.31987,"marketCap":36568379},{"date":"2025-12-26","current":-0.955088,"twenty":-2.897553,"median":-2.584818,"eighty":-1.266827,"marketCap":34145173},{"date":"2026-01-02","current":-1.074791,"twenty":-2.896932,"median":-2.511859,"eighty":-1.220048,"marketCap":38424640},{"date":"2026-01-09","current":-1.095865,"twenty":-2.885734,"median":-2.329463,"eighty":-1.179996,"marketCap":39178064},{"date":"2026-01-16","current":-0.976444,"twenty":-2.885734,"median":-2.178335,"eighty":-1.123965,"marketCap":34908660},{"date":"2026-01-23","current":-0.94132,"twenty":-2.866576,"median":-2.167912,"eighty":-1.101485,"marketCap":33652952},{"date":"2026-01-30","current":-0.878097,"twenty":-2.861786,"median":-2.115799,"eighty":-1.061072,"marketCap":31392680},{"date":"2026-02-06","current":-0.765701,"twenty":-2.861786,"median":-2.074108,"eighty":-1.022014,"marketCap":27374416},{"date":"2026-02-13","current":-0.709738,"twenty":-2.853549,"median":-1.933403,"eighty":-0.974021,"marketCap":25373688},{"date":"2026-02-20","current":-0.786136,"twenty":-2.850483,"median":-1.381324,"eighty":-0.961937,"marketCap":28104981},{"date":"2026-02-27","current":-0.97195,"twenty":-2.849812,"median":-1.344224,"eighty":-0.949581,"marketCap":34747976},{"date":"2026-03-06","current":-0.484474,"twenty":-2.849812,"median":-1.300152,"eighty":-0.949581,"marketCap":17320333},{"date":"2026-03-13","current":-0.412761,"twenty":-2.835443,"median":-1.263181,"eighty":-0.891018,"marketCap":14756541},{"date":"2026-03-20","current":-0.412761,"twenty":-2.825864,"median":-1.220048,"eighty":-0.847322,"marketCap":14756541},{"date":"2026-03-27","current":-0.387698,"twenty":-2.82079,"median":-1.201563,"eighty":-0.836077,"marketCap":18330934},{"date":"2026-04-02","current":-0.349652,"twenty":-2.811211,"median":-1.179996,"eighty":-0.820403,"marketCap":16532085},{"date":"2026-04-10","current":-0.367967,"twenty":-2.792337,"median":-1.125793,"eighty":-0.786136,"marketCap":17398052},{"date":"2026-04-17","current":-0.250001,"twenty":-2.775573,"median":-1.109135,"eighty":-0.744685,"marketCap":11820441},{"date":"2026-04-24","current":-0.276475,"twenty":-2.764797,"median":-1.099378,"eighty":-0.508201,"marketCap":13072156},{"date":"2026-05-01","current":-0.235266,"twenty":-2.75402,"median":-1.088841,"eighty":-0.417566,"marketCap":11123732},{"date":"2026-05-08","current":-0.277717,"twenty":-2.74923,"median":-1.069002,"eighty":-0.412761,"marketCap":13130880},{"date":"2026-05-15","current":-0.393186,"twenty":-2.733353,"median":-1.041354,"eighty":-0.401798,"marketCap":18590424},{"date":"2026-05-22","current":-0.308017,"twenty":-2.714637,"median":-1.024243,"eighty":-0.38811,"marketCap":15777036},{"date":"2026-05-29","current":-0.354651,"twenty":-2.703729,"median":-1.018593,"eighty":-0.376126,"marketCap":18165658},{"date":"2026-06-05","current":-0.402361,"twenty":-2.691755,"median":-0.976444,"eighty":-0.374724,"marketCap":20609444},{"date":"2026-06-12","current":-0.35842,"twenty":-2.672597,"median":-0.968141,"eighty":-0.372398,"marketCap":18358733},{"date":"2026-06-18","current":-0.378775,"twenty":-2.63428,"median":-0.962395,"eighty":-0.367967,"marketCap":19401342},{"date":"2026-06-26","current":-0.492235,"twenty":-2.63428,"median":-0.955088,"eighty":-0.371628,"marketCap":25212882},{"date":"2026-07-02","current":-0.442458,"twenty":-2.59471,"median":-0.94132,"eighty":-0.37203,"marketCap":22663265},{"date":"2026-07-10","current":-0.467347,"twenty":-2.543128,"median":-0.915037,"eighty":-0.3732,"marketCap":23938074},{"date":"2026-07-17","current":-0.449095,"twenty":-2.516028,"median":-0.871896,"eighty":-0.374395,"marketCap":23003214},{"date":"2026-07-24","current":-0.424981,"twenty":-2.511859,"median":-0.846653,"eighty":-0.374627,"marketCap":21768066},{"date":"2026-07-31","current":-0.290474,"twenty":-2.411802,"median":-0.843141,"eighty":-0.371929,"marketCap":14878433},{"date":"2026-08-07","current":-0.34025,"twenty":-2.326336,"median":-0.835949,"eighty":-0.363051,"marketCap":17428051},{"date":"2026-08-14","current":-0.353971,"twenty":-2.282561,"median":-0.821824,"eighty":-0.360424,"marketCap":20056990},{"date":"2026-08-21","current":-0.30351,"twenty":-2.211687,"median":-0.793282,"eighty":-0.354379,"marketCap":17197762}],"updateTime":1787590071951},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622888383","title":"Medicus Pharma Ltd reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622888383","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622888383?lang=en_us&edition=fundamental","pubTime":"2026-03-26 07:07","pubTimestamp":1774480063,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd reports results for the quarter ended December 31 - Earnings SummaryMedicus Pharma Ltd MDCX.OQ reported a quarterly adjusted loss of 65 cents per share for the quarter ended Decembe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D2PP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622900204","title":"Medicus Pharma FY2025 announces SkinJect SKNJCT-003 topline results; net loss climbs to $35.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622900204","media":"Reuters","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622900204?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:50","pubTimestamp":1774471853,"startTime":"0","endTime":"0","summary":"Medicus reported topline results from its SKNJCT-003 Phase 2 study of its SkinJect program, positioning the asset for potential use in non-invasive treatment of nodular basal cell carcinoma.The company said the 200g cohort achieved 73% clinical clearance and 40% histological clearance at Day 57, which could support differentiation versus surgical standard-of-care pathways.Medicus expects completion of the clinical study report in Q2 2026, a step that could enable regulatory planning for the next development stage and potential partnering discussions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and R","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL2kdnzL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622002236","title":"Medicus Pharma Q4 EPS $(0.83) Misses $(0.15) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622002236","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622002236?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:40","pubTimestamp":1774471240,"startTime":"0","endTime":"0","summary":"Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.15) by 442.48 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51470321/medicus-pharma-q4-eps-0-83-misses-0-15-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Medicus Pharma Q4 EPS $(0.83) Misses $(0.15) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004974","title":"Medicus Pharma FY2025 net loss more than doubled to $35.4 million; operating loss tripled to $34.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004974","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004974?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:09","pubTimestamp":1774469374,"startTime":"0","endTime":"0","summary":"Medicus published its annual report  for the fiscal year ended Dec. 31, 2025, reporting a net loss of USD 35.4 million, or USD 2.74 per share.Total operating expenses rose more than tripled to USD 34.4 million, including general and administrative expense of USD 17.9 million and research and development expense of USD 7.7 million.General and administrative expense more than doubled, driven primarily by higher salaries and wages from increased headcount at board and management levels, as well as higher fees and added costs tied to being a public company, multiple financings and the Antev acquisition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDG","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL4tfG4N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621516187","title":"Medicus Pharma Ltd  expected to post a loss of 15 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621516187","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621516187?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:14","pubTimestamp":1774037646,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd  expected to post a loss of15cents a share - Earnings Preview Medicus Pharma Ltd MDCX.OQ MDCX.O is expected to  show no change in quarterly revenue when it reports  results on March","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N40829U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620273711","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620273711","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620273711?lang=en_us&edition=fundamental","pubTime":"2026-03-20 02:54","pubTimestamp":1773946440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2026 14:54 ET (18:54 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620255167","title":"Medicus Pharma Showcases Strong Phase 2 SkinJect Data Ahead of Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2620255167","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620255167?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:24","pubTimestamp":1773836685,"startTime":"0","endTime":"0","summary":"The latest update is out from Medicus Pharma Ltd ( ($MDCX) ). Medicus Pharma will host a live fireside chat on March 19, 2026, led by Executive Cha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-showcases-strong-phase-2-skinject-data-ahead-of-fireside-chat?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-showcases-strong-phase-2-skinject-data-ahead-of-fireside-chat?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620230291","title":"Medicus Pharma executives to join Brookline Capital Markets fireside chat on SkinJect Phase 2 results showing 73% clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2620230291","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620230291?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:30","pubTimestamp":1773833418,"startTime":"0","endTime":"0","summary":"Medicus Pharma executives to join Brookline Capital Markets fireside chat on SkinJect Phase 2 results showing 73% clearance               Medicus will participate in a live fireside chat on March 19, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7Qq9f6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619450364","title":"BRIEF-Medicus Pharma Announces Skinject® Phase 2 Principal Investigator And Key Opinion Leader (Kol), Babar K. Rao MD, Faad, To Provide Clinical Interpretation Of Positive Data During Business Update Webcast On March 26","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450364","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450364?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:38","pubTimestamp":1773661091,"startTime":"0","endTime":"0","summary":"BRIEF-Medicus Pharma Announces Skinject Phase 2 Principal Investigator And Key Opinion Leader (Kol), Babar K. Rao MD, Faad, To Provide Clinical Interpretation Of Positive Data During Business Update W","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA64FBNH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619570894","title":"Medicus Pharma reports 73% clinical clearance in SkinJect Phase 2 nodular basal cell carcinoma trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2619570894","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619570894?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:31","pubTimestamp":1773660692,"startTime":"0","endTime":"0","summary":"Medicus announced that Babar K. Rao will provide clinical interpretation of results from the randomized, double-blind SKNJCT-003 Phase 2 trial evaluating doxorubicin delivered via the SkinJect microneedle platform in patients with nodular basal cell carcinoma. The company said positive topline data have already been reported, and Rao’s interpretation will be presented during a business update webcast on March 26, 2026. In the 200-g cohort at Day 57, clinical clearance was 73% in the doxorubicin microneedle arm versus 38% in the device-only arm, a 35 percentage point difference. The same cohort showed 40% histological clearance at Day 57.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDLbdYw1m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","MDCX","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","IE00BKPKM429.USD","BK4139","LU2095319765.USD","SG9999014021.USD","SG9999014039.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4112","SG9999014013.SGD","LU2210150020.SGD","BK4585","BK4588","LU0314104364.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618955533","title":"Medicus Pharma to Spotlight AI-Driven Drug Development at Longwood Miami CEO Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2618955533","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618955533?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:15","pubTimestamp":1773148534,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd ( ($MDCX) ) has issued an announcement. Medicus Pharma Ltd. will participate in the invitation-only Longwood Miami CEO Forum, wh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-to-spotlight-ai-driven-drug-development-at-longwood-miami-ceo-forum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-to-spotlight-ai-driven-drug-development-at-longwood-miami-ceo-forum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FET","BK4179","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618625937","title":"Medicus Pharma CEO to speak at Longwood Miami CEO Forum panel","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625937","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618625937?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:49","pubTimestamp":1773143367,"startTime":"0","endTime":"0","summary":"Medicus Pharma CEO to speak at Longwood Miami CEO Forum panel               Medicus will attend the Longwood Miami CEO forum on March 11-13, 2026, at the Ritz-Carlton Key Biscayne. Dr. Raza Bokhari is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL4MFBgY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618760066","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2618760066","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618760066?lang=en_us&edition=fundamental","pubTime":"2026-03-10 02:40","pubTimestamp":1773081600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 14:40 ET (18:40 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618621897","title":"Medicus Pharma Highlights Strong Phase 2 SkinJect Results in Basal Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621897","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618621897?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:19","pubTimestamp":1773062385,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd ( ($MDCX) ) has shared an announcement. Medicus Pharma has released an interpretation of Phase 2 data for its SkinJect microneed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-highlights-strong-phase-2-skinject-results-in-basal-cell-carcinoma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-highlights-strong-phase-2-skinject-results-in-basal-cell-carcinoma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618614623","title":"Medicus Pharma provides interpretation of Phase 2 SkinJect dataset","url":"https://stock-news.laohu8.com/highlight/detail?id=2618614623","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618614623?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:40","pubTimestamp":1773056433,"startTime":"0","endTime":"0","summary":"Medicus Pharma (MDCX) provided additional context regarding the recently reported topline dataset from the Phase 2 SKNJCT-003 study evaluating Skin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-provides-interpretation-of-phase-2-skinject-dataset-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-provides-interpretation-of-phase-2-skinject-dataset-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618662809","title":"Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset","url":"https://stock-news.laohu8.com/highlight/detail?id=2618662809","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618662809?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:30","pubTimestamp":1773055800,"startTime":"0","endTime":"0","summary":"The Company Reported 73% Clinical Clearance in the 200-g cohort at Day 57PHILADELPHIA, March  09, 2026  (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (\"Medicus\" or the \"Company\"), a biotech/l","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251726/0/en/Medicus-Pharma-Provides-Interpretation-of-Positive-Phase-2-SkinJect-Dataset.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0149725797.USD","LU1935042991.SGD","APC","LU2420271590.USD","BCC","LU1066051811.HKD","LU1366333091.USD","LU2237443382.USD","MNA","LU2417539215.USD","LU1778281490.HKD","LU1718418525.SGD","BK4567","LU2236285917.USD","MDCX","BK4139","LU1066053197.SGD","LU0170899867.USD","LU1935043023.USD","LU2237443978.SGD","LU1674673428.USD","LU0053666078.USD","LU0882574139.USD","LU1496350171.SGD","LU2456880835.USD","LU2083900584.USD","LU2237443549.SGD","LU1935043536.SGD","LU0786609619.USD","LU1674673691.USD","LU1935042488.USD","LU1066051498.USD","BK4214","LU0077335932.USD","LU0157215616.USD","LU1935042215.USD","BK4104","LU0314104364.USD","LU1366192091.USD","LU1066051225.USD","LU2237443622.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617781653","title":"Medicus Pharma Raises Equity Financing, Reduces Yorkville Debenture","url":"https://stock-news.laohu8.com/highlight/detail?id=2617781653","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617781653?lang=en_us&edition=fundamental","pubTime":"2026-03-07 06:05","pubTimestamp":1772834716,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Medicus Pharma Ltd ( ($MDCX) ). Medicus Pharma Ltd. disclosed that, under its Standby Equity Purchase Agreement...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-raises-equity-financing-reduces-yorkville-debenture?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-raises-equity-financing-reduces-yorkville-debenture?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4215","EQR","BK4585","BK4139","BK4588","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617658219","title":"Medicus Pharma Sells 4.47M Shares to Yorkville for $3.85M Under SEPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2617658219","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617658219?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:41","pubTimestamp":1772833299,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. reported unregistered sales of common shares to YA II PN, Ltd.  under its standby equity purchase agreement dated Feb. 10, 2025. The company sold a total of 4,471,038 shares for approximately $3,846,910 in proceeds across multiple transactions from Dec. 19, 2025 through March 6, 2026. Medicus said it used part of the net proceeds to prepay a portion of its outstanding debenture with Yorkville, and that the shares were issued in reliance on the Securities Act Section 4 exemption.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL3wjWzB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617786544","title":"Medicus Pharma Reports Phase 2 SkinJect D-MNA Data Showing 73% Clinical Clearance in Basal Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2617786544","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617786544?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:31","pubTimestamp":1772713877,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. reported topline results from its Phase 2 SKNJCT-003 randomized, double-blind, placebo-controlled study evaluating a doxorubicin microneedle array  for non-invasive treatment of nodular basal cell carcinoma. The trial enrolled 90 patients across placebo, 100μg D-MNA, and 200μg D-MNA groups; at Day 57, the 200μg cohort showed 73% clinical clearance and 40% histological clearance, compared with 38% and 38% for placebo. The results have already been presented as topline data, while the full clinical study report, including safety analyses, is expected in Q2 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief on March 05, 2026, and is s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL1nslYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617544242","title":"Medicus Pharma Reports Positive Phase 2 Sknjct-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (Cr) at Day 57 in 200ΜG Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2617544242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617544242?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:30","pubTimestamp":1772713801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA3QTBWY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":106,"code":"91000000","status":"200"}]}}